Anti-EDEM2/ C20orf31/ C20orf49 functional antibody

Anti-EDEM2/ C20orf31/ C20orf49 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to EDEM2/EDEM2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1428-Ab-1/ GM-Tg-hg-SE1428-Ab-2Anti-Human EDEM2 monoclonal antibodyHuman
GM-Tg-rg-SE1428-Ab-1/ GM-Tg-rg-SE1428-Ab-2Anti-Rat EDEM2 monoclonal antibodyRat
GM-Tg-mg-SE1428-Ab-1/ GM-Tg-mg-SE1428-Ab-2Anti-Mouse EDEM2 monoclonal antibodyMouse
GM-Tg-cynog-SE1428-Ab-1/ GM-Tg-cynog-SE1428-Ab-2Anti-Cynomolgus/ Rhesus macaque EDEM2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1428-Ab-1/ GM-Tg-felg-SE1428-Ab-2Anti-Feline EDEM2 monoclonal antibodyFeline
GM-Tg-cang-SE1428-Ab-1/ GM-Tg-cang-SE1428-Ab-2Anti-Canine EDEM2 monoclonal antibodyCanine
GM-Tg-bovg-SE1428-Ab-1/ GM-Tg-bovg-SE1428-Ab-2Anti-Bovine EDEM2 monoclonal antibodyBovine
GM-Tg-equg-SE1428-Ab-1/ GM-Tg-equg-SE1428-Ab-2Anti-Equine EDEM2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1428-Ab-1/ GM-Tg-hg-SE1428-Ab-2; GM-Tg-rg-SE1428-Ab-1/ GM-Tg-rg-SE1428-Ab-2;
GM-Tg-mg-SE1428-Ab-1/ GM-Tg-mg-SE1428-Ab-2; GM-Tg-cynog-SE1428-Ab-1/ GM-Tg-cynog-SE1428-Ab-2;
GM-Tg-felg-SE1428-Ab-1/ GM-Tg-felg-SE1428-Ab-2; GM-Tg-cang-SE1428-Ab-1/ GM-Tg-cang-SE1428-Ab-2;
GM-Tg-bovg-SE1428-Ab-1/ GM-Tg-bovg-SE1428-Ab-2; GM-Tg-equg-SE1428-Ab-1/ GM-Tg-equg-SE1428-Ab-2
Products NameAnti-EDEM2 monoclonal antibody
Formatmab
Target NameEDEM2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-EDEM2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1428-Ag-1Recombinant multi-species EDEM2/ C20orf31/ C20orf49 protein


    Target information

    Target IDGM-SE1428
    Target NameEDEM2
    Gene ID55741,108687,296304,706150,100054608
    Gene Symbol and Synonyms9530090G24Rik,bA4204.1,C20orf31,C20orf49,EDEM2,RGD1303074
    Uniprot AccessionQ9BV94
    Uniprot Entry NameEDEM2_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000088298
    Target ClassificationN/A

    The target: EDEM2, gene name: EDEM2, also named as C20orf31, C20orf49, bA4204.1. In the endoplasmic reticulum (ER), misfolded proteins are retrotranslocated to the cytosol and degraded by the proteasome in a process known as ER-associated degradation (ERAD). EDEM2 belongs to a family of proteins involved in ERAD of glycoproteins (Mast et al., 2005 [PubMed 15537790]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.